^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCL6 fusion + NOTCH2 mutation

    i
    Other names: BCL6, BCL5, BCL6A, LAZ3, ZBTB27, ZNF51, B-cell CLL/lymphoma 6, NOTCH2, Notch Receptor 2, Notch 2, Neurogenic Locus Notch Homolog Protein 2, Notch (Drosophila) Homolog 2, Notch Homolog 2, AGS2
    Entrez ID:
    604; 4853
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    6ms
    Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study (ASH 2023)
    Introduction: In the POLARIX study, polatuzumab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated prolonged progression-free survival (PFS) vs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL; NCT03274492; Tilly et al. In this exploratory biomarker analysis, we recapitulated that pts with molecularly defined DLBCL subtypes, including EZB and MCD by LymphGen and DZsig+ by RNAseq, have poor outcomes with R-CHOP therapy. In pts with the EZB and MCD subtypes, Pola-R-CHP appeared to improve 2-year PFS compared with R-CHOP. Pts with GCB DLBCL who were DZsig+ significantly benefited from Pola-R-CHP vs R-CHOP.
    Clinical • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2)
    |
    EZH2 mutation • CD79B mutation • CD79B mutation • MYC translocation • NOTCH2 mutation • BCL6 translocation • BCL6 fusion + NOTCH2 mutation • BCL2 translocation • BCL6 fusion
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Polivy (polatuzumab vedotin-piiq)